GSK revs up launch plans after Nucala's FDA approval in COPD, targeting £500M opportunity

The FDA has approved GSK's Nucala as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, making it the second biologic approved for this condition. This approval, supported by the Matinee study showing a 21% reduction in moderate or severe COPD exacerbations, positions Nucala to compete with Sanofi and Regeneron’s Dupixent, although GSK highlights Nucala's broader patient inclusion criteria and potential to reduce hospitalizations. GSK anticipates peak year sales of 500 million pounds sterling for Nucala in COPD, leveraging its existing COPD portfolio and established pricing structure.

Analysis

The U.S. Food and Drug Administration's (FDA) approval of GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype marks a significant expansion for the IL-5 antibody. This green light, following an unexpected two-week delay, positions Nucala as the second biologic approved for this condition, setting up direct competition with Sanofi and Regeneron’s Dupixent, which targets a similar eosinophil-high patient population. GSK aims to differentiate Nucala by highlighting its broader patient inclusion criteria in the Phase 3 Matinee study, which encompassed patients with chronic bronchitis, emphysema, or both; this contrasts with Dupixent's trial population which did not include emphysema-only patients. The Matinee study demonstrated Nucala's efficacy, achieving a 21% reduction in the annualized rate of moderate or severe COPD exacerbations versus placebo and, critically, a 35% reduction in exacerbations leading to emergency room visits or hospitalizations. GSK underscores the importance of reducing hospitalizations, given the severe prognosis following such events for COPD patients. The company projects peak annual sales of 500 million pounds sterling (approximately $669 million) for Nucala in the COPD indication, maintaining its existing pricing structure of around $3,800 per dose before discounts. This new indication is expected to bolster Nucala's growth, which saw total sales across its prior four indications reach 3.3 billion pounds in 2024 (a 13% increase at constant currencies) and 444 million pounds in the first quarter of 2025 (a 21% year-over-year increase). GSK will leverage its established presence in the COPD market, where its Trelegy Ellipta is already a leading product, through further outreach and education.

Key Decisions for Investors

• Investors should closely monitor Nucala's market adoption rate in the COPD segment, particularly its ability to capture market share from Sanofi/Regeneron's Dupixent, to validate GSK's 500 million pounds sterling peak sales forecast.
• Consider the competitive advantage Nucala's broader patient label and demonstrated reduction in hospitalizations might offer in terms of physician preference and formulary access within the eosinophilic COPD patient population.
• Evaluate the incremental revenue contribution from Nucala's COPD indication to GSK's overall respiratory franchise and its impact on the company's earnings growth, given the drug's established pricing and strong sales momentum in existing indications.